By IDSE News Staff
The FDA approved tenofovir alafenamide (TAF; Vemlidy, Gilead) 25 mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.
TAF will have a boxed warning regarding the risks for lactic acidosis/severe hepatomegaly with steatosis and post-treatment severe acute exacerbation of HBV.
TAF is a novel, targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to and at a dose less than one-tenth that of